Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9619196 | 0.86 | KDM4E (0.58) | KMT2AKDM4EHTTALDH1A1HPGD | |
| SCHEMBL38827 | 0.86 | MAPT (0.57) | MAPTL3MBTL1KMT2AKDM4EHTT | |
| SCHEMBL12110268 | 0.86 | KMT2A (0.56) | MAPTKMT2AKDM4EHTTALDH1A1 | |
| SCHEMBL1308905 | 0.86 | MAPT (0.61) | MAPTL3MBTL1KMT2AKDM4EHTT | |
| SCHEMBL22924660 | 0.82 | HRH4 (0.47) | MAPTL3MBTL1KMT2AHTTMAPK1 | |
| SCHEMBL20805760 | 0.82 | MAPK1 (0.44) | MAPTL3MBTL1KMT2AHTTALDH1A1 | |
| SCHEMBL2689185 | 0.81 | KMT2A (0.49) | MAPTL3MBTL1KMT2AKDM4EHTT | |
| SCHEMBL28998051 | 0.81 | ALDH1A1 (0.59) | MAPTL3MBTL1KMT2AKDM4EHTT | |
| SCHEMBL19295119 | 0.81 | MAPK1 (0.47) | L3MBTL1KMT2AHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL1310780 | 0.80 | MAPT (0.60) | MAPTL3MBTL1KMT2AKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399302-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS | NATIONAL INSTITUTES OF HEALTH | 2023-12-14 | — | — | US | disclosed |
| US-20230129089-A1 | PREPARATION OF A 1,3,5-TRIAZINYL BENZIMIDAZOLE | MEI PHARMA, INC. | 2023-04-27 | — | — | US | disclosed |
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020058337-A1 | USE OF A MELAMINE BASED COMPOUND AND A HALS COMPOUND AS HEAT STABILIZER IN POLYMERS | BOREALIS AG (AT) | 2020-03-26 | — | — | WO | disclosed |
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| WO-2017198346-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2017-11-23 | — | — | WO | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20070113356-A1 | Reactive polysaccharide derivatives, their preparation and their use | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070113356-A1 | Reactive polysaccharide derivatives, their preparation and their use | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-05-24 | — | — | US | disclosed |
| EP-1765325-A2 | 2-SUBSTITUTED HETEROARYL COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7169835-B2 | Stabilizer mixture | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060063739-A1 | 2-Substituted heteroaryl compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-03-23 | — | — | US | disclosed |
| WO-2006007532-A2 | 2-SUBSTITUTED HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-6342503-B1 | ANTIDEPRESSANTS, EATING DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2002-01-29 | — | — | US | disclosed |
| US-6107301-A | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0723533-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010506-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129089-A1 | PREPARATION OF A 1,3,5-TRIAZINYL BENZIMIDAZOLE | CYP2E1, CYP3A4, PAICS | MAPT 2578/4885L3MBTL1 2936/4885KMT2A 1897/4885 |
| US-20070113356-A1 | Reactive polysaccharide derivatives, their preparation and their use | C1S, H1-0, H1-4 | MAPT 4550/4885L3MBTL1 2580/4885KMT2A 2501/4885 |
| US-20230399302-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS | TST, TYR, STS | MAPT 3431/4885L3MBTL1 3794/4885KMT2A 1707/4885 |
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | MAPT 1084/4885L3MBTL1 3160/4885KMT2A 2922/4885 |
| US-20060063739-A1 | 2-Substituted heteroaryl compounds | IL2, IL4, IL2RA | MAPT 1171/4885L3MBTL1 4762/4885KMT2A 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.